Newsroom
Featured News
- Business03 December 2025
Alvogen US Acquisition Completed; Lotus Strengthens Global Specialty Pharma Platform
- Business01 December 2025
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
- Business24 November 2025
Taiwan DIR Grants Approval for Lotus’ Acquisition of Alvogen US, Aiming 2025 Year-End Closing
- Investors12 November 2025
Lotus Pharmaceutical Reports Results for the Third Quarter and First Nine Months of 2025
- Investors10 November 2025
Lotus Reports October 2025 Revenue of NT$2,753 Million
- Investors09 October 2025
Lotus reports September 2025 Revenue of NT$1,214 Million
- Business03 October 2025
Lotus Enters License and Supply Agreement With Adalvo for Semaglutide injection (Wegovy® & Ozempic® 2mg generic)
- Business24 September 2025
Lotus Pharmaceutical to Acquire Alvogen US, Creating a Top 20 Global Specialty Pharma Powerhouse
- Investors10 September 2025
Lotus reports August 2025 Revenue of NT$1,160 Million
